{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:31:54Z","timestamp":1769517114992,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polypoidal choroidal vasculopathy (PCV) is a vision-threatening disease common in Asian populations. However, the optimal treatment for PCV remains under debate. We searched the databases with optimal searching strategy. The study included randomized clinical trials and prospective studies that recruited patients with active PCV who had received interventions, including PDT, anti-VEGF, or a combination of PDT and anti-VEGF. The Grading of Recommendations Assessment, Development, and Evaluation methodology was used for rating the quality of evidence. Our study included 11 studies involving 1277 patients. The network meta-analysis of RCTs revealed the anti-VEGF group, early combination group, and late combination group had significant BCVA changes compared with the PDT group. Early combination therapy led to a significant decrease in CRT compared with PDT, anti-VEGF, and late combination therapy. Additionally, the early combination group had a significantly higher complete polyp regression rate than the anti-VEGF group. No significant differences were detected in the analysis of the number of anti-VEGF injections and safety profile. This network meta-analysis revealed that early combination therapy exhibited better efficacy related to anatomical outcomes than other therapies. Nonetheless, no significant differences related to BCVA change could be detected between anti-VEGF and late combination therapy.<\/jats:p>","DOI":"10.1038\/s41598-021-82316-y","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T13:21:09Z","timestamp":1612272069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy"],"prefix":"10.1038","volume":"11","author":[{"given":"Sheng-Chu","family":"Chi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-No","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"82316_CR1","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung, C. M. G. et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology 125, 708\u2013724. https:\/\/doi.org\/10.1016\/j.ophtha.2017.11.019 (2018).","journal-title":"Ophthalmology"},{"key":"82316_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown, D. M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355, 1432\u20131444. https:\/\/doi.org\/10.1056\/NEJMoa062655 (2006).","journal-title":"N Engl J Med"},{"key":"82316_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355, 1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481 (2006).","journal-title":"N Engl J Med"},{"key":"82316_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.preteyeres.2013.09.003","volume":"37","author":"P Nowak-Sliwinska","year":"2013","unstructured":"Nowak-Sliwinska, P., van den Bergh, H., Sickenberg, M. & Koh, A. H. Photodynamic therapy for polypoidal choroidal vasculopathy. Progress Retinal Eye Res. 37, 182\u2013199. https:\/\/doi.org\/10.1016\/j.preteyeres.2013.09.003 (2013).","journal-title":"Progress Retinal Eye Res."},{"key":"82316_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajo.2007.03.014","volume":"144","author":"A Otani","year":"2007","unstructured":"Otani, A. et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 144, 7\u201314. https:\/\/doi.org\/10.1016\/j.ajo.2007.03.014 (2007).","journal-title":"Am. J. Ophthalmol."},{"key":"82316_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/eye.2015.251","volume":"30","author":"DK Newman","year":"2016","unstructured":"Newman, D. K. Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye 30, 202\u2013210. https:\/\/doi.org\/10.1038\/eye.2015.251 (2016).","journal-title":"Eye"},{"key":"82316_CR7","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh, A. et al. Everest study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32, 1453\u20131464. https:\/\/doi.org\/10.1097\/IAE.0b013e31824f91e8 (2012).","journal-title":"Retina"},{"key":"82316_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","volume":"156","author":"A Oishi","year":"2013","unstructured":"Oishi, A. et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am. J. Ophthalmol. 156, 644\u2013651. https:\/\/doi.org\/10.1016\/j.ajo.2013.05.024 (2013).","journal-title":"Am. J. Ophthalmol."},{"key":"82316_CR9","doi-asserted-by":"publisher","unstructured":"9Gomi, F. et al. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: the Fujisan Study. Retina (philadelphia, pa.) 35, 1569\u20101576, https:\/\/doi.org\/10.1097\/IAE.0000000000000526 (2015).","DOI":"10.1097\/IAE.0000000000000526"},{"key":"82316_CR10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh, A. et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 135, 1206\u20131213. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4030 (2017).","journal-title":"JAMA Ophthalmol."},{"key":"82316_CR11","unstructured":"11Lai, T. Y. Y., Feller, C., Margaron, P. & Tan, C. S. Anatomical outcomes of ranibizumab 0.5 mg combined with verteporfin photodynamic therapy vs ranibizumab monotherapy in patients with polypoidal choroidal vasculopathy: 12-month results from the EVEREST II study. Investigative Ophthalmol. Vis. Sci. 58 (2017)."},{"key":"82316_CR12","doi-asserted-by":"publisher","unstructured":"12Chen, S.-N. et al. One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study. Int. J. Ophthalmol. 11, 1802\u20131808, https:\/\/doi.org\/10.18240\/ijo.2018.11.11 (2018).","DOI":"10.18240\/ijo.2018.11.11"},{"key":"82316_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12886-018-0801-7","volume":"18","author":"K Lai","year":"2018","unstructured":"Lai, K. et al. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen. BMC Ophthalmol 18, 144\u2013144. https:\/\/doi.org\/10.1186\/s12886-018-0801-7 (2018).","journal-title":"BMC Ophthalmol"},{"key":"82316_CR14","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee, W. K. et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the planet study: a randomized clinical trial. JAMA Ophthalmol. 136, 786\u2013793. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.1804 (2018).","journal-title":"JAMA Ophthalmol."},{"key":"82316_CR15","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.3892\/etm.2017.5565","volume":"15","author":"J Li","year":"2018","unstructured":"Li, J., Sun, J., Li, B. & Liu, Z. Intravitreal ranibizumab injection combined with photodynamic therapy for polypoidal choroidal vasculopathy. Exp. Ther. Med. 15, 1546\u20131551. https:\/\/doi.org\/10.3892\/etm.2017.5565 (2018).","journal-title":"Exp. Ther. Med."},{"key":"82316_CR16","doi-asserted-by":"publisher","unstructured":"16Teo, K. Y. C. et al. Comparison of optical coherence tomography angiographic changes after anti-vascular endothelial growth factor therapy alone or in combination with photodynamic therapy in polypoidal choroidal vasculopathy. Retina (Philadelphia, Pa.) 38, 1675\u20131687, https:\/\/doi.org\/10.1097\/IAE.0000000000001776 (2018).","DOI":"10.1097\/IAE.0000000000001776"},{"key":"82316_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1755-3768.2009.01841.x","volume":"90","author":"JY Lim","year":"2012","unstructured":"Lim, J. Y. et al. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol. 90, 61\u201367. https:\/\/doi.org\/10.1111\/j.1755-3768.2009.01841.x (2012).","journal-title":"Acta Ophthalmol."},{"key":"82316_CR18","doi-asserted-by":"publisher","unstructured":"18Chong Teo, K. Y. et al. A Multicountry comparison of real-world management and outcomes of polypoidal choroidal vasculopathy: fight retinal blindness! cohort. Ophthalmol Retina 3, 220\u2013229, https:\/\/doi.org\/10.1016\/j.oret.2018.11.003 (2019).","DOI":"10.1016\/j.oret.2018.11.003"},{"key":"82316_CR19","doi-asserted-by":"publisher","first-page":"e110667","DOI":"10.1371\/journal.pone.0110667","volume":"9","author":"W Wang","year":"2014","unstructured":"Wang, W., He, M. & Zhang, X. Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies. PLoS ONE 9, e110667\u2013e110667. https:\/\/doi.org\/10.1371\/journal.pone.0110667 (2014).","journal-title":"PLoS ONE"},{"key":"82316_CR20","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3980\/j.issn.2222-3959.2015.05.36","volume":"8","author":"K Tang","year":"2015","unstructured":"Tang, K. et al. Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysis. Int. J. Ophthalmol. 8, 1056\u20131066. https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2015.05.36 (2015).","journal-title":"Int. J. Ophthalmol."},{"key":"82316_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12886-015-0064-5","volume":"15","author":"M Yong","year":"2015","unstructured":"Yong, M., Zhou, M. & Deng, G. Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: a meta-analysis. BMC Ophthalmol. 15, 82\u201382. https:\/\/doi.org\/10.1186\/s12886-015-0064-5 (2015).","journal-title":"BMC Ophthalmol."},{"key":"82316_CR22","doi-asserted-by":"publisher","first-page":"e12840","DOI":"10.1111\/eci.12840","volume":"48","author":"T Qian","year":"2018","unstructured":"Qian, T., Li, X., Zhao, M. & Xu, X. Polypoidal choroidal vasculopathy treatment options: A meta-analysis. Eur. J. Clin. Invest. 48, e12840. https:\/\/doi.org\/10.1111\/eci.12840 (2018).","journal-title":"Eur. J. Clin. Invest."},{"key":"82316_CR23","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1097\/iae.0000000000000499","volume":"35","author":"CW Wong","year":"2015","unstructured":"Wong, C. W. et al. THREE-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: retrospective study and systematic review. RETINA 35, 1577\u20131593. https:\/\/doi.org\/10.1097\/iae.0000000000000499 (2015).","journal-title":"RETINA"},{"key":"82316_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/OPTH.S129164","volume":"11","author":"A Arakawa","year":"2017","unstructured":"Arakawa, A., Inoue, M., Sato, S., Yamane, S. & Kadonosono, K. Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy. Clin. Ophthalmol. 11, 797\u2013802. https:\/\/doi.org\/10.2147\/OPTH.S129164 (2017).","journal-title":"Clin. Ophthalmol."},{"key":"82316_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00417-016-3489-5","volume":"255","author":"JE Lee","year":"2017","unstructured":"Lee, J. E. et al. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study. Graefes Arch. Clin. Exp. Ophthalmol. 255, 493\u2013502. https:\/\/doi.org\/10.1007\/s00417-016-3489-5 (2017).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"82316_CR26","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00417-014-2838-5","volume":"253","author":"Y Kawashima","year":"2015","unstructured":"Kawashima, Y. et al. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 253, 1471\u20131477. https:\/\/doi.org\/10.1007\/s00417-014-2838-5 (2015).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"82316_CR27","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.2147\/OPTH.S172115","volume":"12","author":"K Azuma","year":"2018","unstructured":"Azuma, K. et al. Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients. Clin. Ophthalmol. 12, 1589\u20131597. https:\/\/doi.org\/10.2147\/OPTH.S172115 (2018).","journal-title":"Clin. Ophthalmol."},{"key":"82316_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2016.02.019","volume":"165","author":"HJ Cho","year":"2016","unstructured":"Cho, H. J. et al. Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 165, 1\u20136. https:\/\/doi.org\/10.1016\/j.ajo.2016.02.019 (2016).","journal-title":"Am. J. Ophthalmol."},{"key":"82316_CR29","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41598-019-38504-y","volume":"9","author":"BJ Jung","year":"2019","unstructured":"Jung, B. J. et al. Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. Sci. Rep. 9, 2055. https:\/\/doi.org\/10.1038\/s41598-019-38504-y (2019).","journal-title":"Sci. Rep."},{"key":"82316_CR30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/bjophthalmol-2018-311963","volume":"103","author":"M Miyata","year":"2019","unstructured":"Miyata, M. et al. Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 103, 617. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-311963 (2019).","journal-title":"Br. J. Ophthalmol."},{"key":"82316_CR31","doi-asserted-by":"publisher","first-page":"e0229231","DOI":"10.1371\/journal.pone.0229231","volume":"15","author":"K Wataru","year":"2020","unstructured":"Wataru, K. et al. Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. PLoS ONE 15, e0229231. https:\/\/doi.org\/10.1371\/journal.pone.0229231 (2020).","journal-title":"PLoS ONE"},{"key":"82316_CR32","unstructured":"32Schmidt-Erfurth, U., Laqua, H., Schl\u00f6tzer-Schrehard, U., Viestenz, A. & Naumann, G. O. Histopathological changes following photodynamic therapy in human eyes. Arch. Ophthalmol. (Chicago, Ill. : 1960) 120, 835\u2013844 (2002)."},{"key":"82316_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/ceo.13049\/full","volume":"45","author":"P Mitchell","year":"2017","unstructured":"Mitchell, P. et al. Intravitreal aflibercept (IVT-AFL) with and without photodynamic therapy (PDT) in polypoidal choroidal vasculopathy (PCV): anatomical outcomes assessed by optical coherence tomography (OCT) in the planet study. Clin. Exp. Ophthalmol. 45, 31\u201332. https:\/\/doi.org\/10.1111\/ceo.13049\/full (2017).","journal-title":"Clin. Exp. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82316-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82316-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82316-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:50:47Z","timestamp":1670035847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82316-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82316"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82316-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"8 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2735"}}